Welcome to our dedicated page for SELB news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on SELB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SELB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SELB's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cellarity, a life sciences company, has announced several key leadership appointments to enhance its innovative drug discovery platform. John Leaman, M.D., M.B.A., joins as Chief Financial Officer, bringing extensive experience from Impel Pharmaceuticals, Selecta Biosciences, and Medgenics. Cameron Trenor, M.D., is appointed as Vice President and Head of Translational Medicine, with a strong background in hematology drug development. Anjali Kumar, Ph.D., takes on the role of Vice President, Head of Business Development, previously leading innovation at Johnson & Johnson. Additionally, Parul Doshi, M.B.A., has been promoted to Chief Data Officer. These changes aim to accelerate Cellarity's progress towards its clinical pipeline, leveraging its proprietary AI platform to create novel drug candidates for complex diseases.
On March 21, 2023, Selecta Biosciences (NASDAQ: SELB) reported positive topline results from its Phase 3 DISSOLVE I and II trials for SEL-212, an investigational treatment for chronic refractory gout. In DISSOLVE I, 56% of patients achieved a response at a high dose, significantly outperforming the placebo rate of 4%. DISSOLVE II showed a 47% response rate at the same dosage compared to 12% for placebo. The treatment demonstrated a 69% reduction in serum urate levels and maintained a favorable safety profile, with only 3.4% of patients experiencing infusion reactions. The company aims to file for U.S. marketing approval in the first half of 2024.
